Biopharma Products
For healthcare professionals only. This content contains promotional and brand information.
Prescribing information is available in the downloads section below. Adverse event reporting details are also available at the bottom of this webpage.
Bomyntra®▼(denosumab)
Conexxence®▼ (denosumab)
Idacio® (adalimumab)
Tyenne®▼(tocilizumab)
Prescribing information download links:
Bomyntra Prescribing Information
Bomyntra Prescribing Information
- Filename
- Bomyntra Prescribing Information.pdf
- Size
- 224 KB
- Format
- Filename
- Conexxence Prescribing Information.pdf
- Size
- 216 KB
- Format
- Filename
- Idacio Prescribing Information.pdf
- Size
- 607 KB
- Format
- Filename
- Tyenne Prescribing Information February 2026.pdf
- Size
- 251 KB
- Format
Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk Adverse events should also be reported to Fresenius Kabi Ltd. Cestrian Court, Eastgate Way, Manor Park, Runcorn, Cheshire, WA7 1NT Tel +44 (0)800 090 2513. Email: pharmacovigilance.gb@fresenius-kabi.com
GB-BOM-2600001 March 2026